SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Los Maartje)
 

Search: WFRF:(Los Maartje) > Severe fluoropyrimi...

Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing

van Kuilenburg, André B P (author)
Meijer, Judith (author)
Maurer, Dirk, 1985- (author)
Uppsala universitet,Biokemi,Dobritzsch
show more...
Dobritzsch, Doreen, 1972- (author)
Uppsala universitet,Biokemi,Dobritzsch
Meinsma, Rutger (author)
Los, Maartje (author)
Knegt, Lia C (author)
Zoetekouw, Lida (author)
Jansen, Rob L H (author)
Dezentjé, Vincent (author)
van Huis-Tanja, Lieke H (author)
van Kampen, Roel J W (author)
Hertz, Jens Michael (author)
Hennekam, Raoul C M (author)
show less...
 (creator_code:org_t)
Elsevier BV, 2017
2017
English.
In: Biochimica et Biophysica Acta. - : Elsevier BV. - 0006-3002 .- 1878-2434. ; 1863:3, s. 721-730
  • Journal article (peer-reviewed)
Abstract Subject headings
Close  
  • Dihydropyrimidine dehydrogenase (DPD) is the initial and rate-limiting enzyme in the catabolism of 5-fluorouracil (5FU). Genetic variations in DPD have emerged as predictive risk factors for severe fluoropyrimidine toxicity. Here, we report novel and rare genetic variants underlying DPD deficiency in 9 cancer patients presenting with severe fluoropyrimidine-associated toxicity. All patients possessed a strongly reduced DPD activity, ranging from 9 to 53% of controls. Analysis of the DPD gene (DPYD) showed the presence of 21 variable sites including 4 novel and 4 very rare aberrations: 3 missense mutations, 2 splice-site mutations, 1 intronic mutation, a deletion of 21 nucleotides and a genomic amplification of exons 9-12. Two novel/rare variants (c.2843T>C, c.321+1G>A) were present in multiple, unrelated patients. Functional analysis of recombinantly-expressed DPD mutants carrying the p.I948T and p.G284V mutation showed residual DPD activities of 30% and 0.5%, respectively. Analysis of a DPD homology model indicated that the p.I948T and p.G284V mutations may affect electron transfer and the binding of FAD, respectively. cDNA analysis showed that the c.321+1G>A mutation in DPYD leads to skipping of exon 4 immediately upstream of the mutated splice-donor site in the process of DPD pre-mRNA splicing. A lethal toxicity in two DPD patients suggests that fluoropyrimidines combined with other therapies such as radiotherapy might be particularly toxic for DPD deficient patients. Our study advocates a more comprehensive genotyping approach combined with phenotyping strategies for upfront screening for DPD deficiency to ensure the safe administration of fluoropyrimidines.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Medicinsk genetik (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Medical Genetics (hsv//eng)

Keyword

Dihydropyrimidine dehydrogenase
DPYD
5-Fluorouracil
Capecitabine
Pharmacogenetics
Toxicity

Publication and Content Type

ref (subject category)
art (subject category)

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view